Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)
Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up). British Journal Of Dermatology 2024, ljae404. PMID: 39438067, DOI: 10.1093/bjd/ljae404.Peer-Reviewed Original ResearchAtopic dermatitisSecondary endpointsDose escalationOpen-labelClinical responseSafety profile of upadacitinibSafety signalsResponse to systemic therapyPruritus Numerical Rating ScaleSafety of upadacitinibEczematous skin lesionsWeeks of treatmentNumerical rating scaleSeverity Index reductionsChronic skin diseasePost hoc analysisPhase 3b/4Systemic therapyItch responseSystemic treatmentPrimary endpointEczema AreaDupilumabSafety profileSuperior efficacy696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
Prajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.Peer-Reviewed Original ResearchSkin symptom severityPatient-reported outcomesAtopic dermatitisSkin painClinically meaningful improvementsUpadacitinib monotherapyPatients treated with upadacitinibPatients randomized to placeboSkin symptomsMeaningful improvementsQuality of lifeTreating moderate-to-severe ADModerate-to-severe ADPhase 3 studyDoses of upadacitinibMinimal clinically important differenceSustained improvementJanus kinase inhibitorsClinically important differenceEvaluate long-term benefitsReduced quality of lifeEczema AreaDLQI 0/1Symptom severityKinase inhibitors